AI-driven LNP design: unlocking non-viral delivery for cell and gene therapy
Cell and Gene Therapy Insights · 05.08.2026 · 12 (6) · 685-690
DOI: 10.18609/cgti.2026.082 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell and Gene Therapy Insights, online erschienen am 05.08.2026. Verfasst von Bowen Li. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Bowen Li, GSK Chair Professor in Drug Delivery & Pharmaceutics and Research Chair in RNA Vaccine & Therapeutics, University of Toronto, speaks with Abi Pinchbeck, Editor, Cell & Gene Therapy Insights , about how his lab is using AI guided delivery design and machine learning to develop programmable lipid nanoparticles for non-viral nucleic acid delivery for cell and gene therapy applications. Bowen Li’s research focuses on making nucleic acid medicines programmable across different tissues using AI-guided delivery design. His lab addresses key challenges in non-viral gene editing delivery, including improving efficiency, safety, and repeat dosing, while developing lipid nanoparticles (LNPs) tailored to specific tissues and complex gene-editing cargos. By combining machine learning, high-throughput in vivo screening, and programmable RNA systems, the team aims to shift nanoparticle development from trial- and -error approaches toward predictive engineering and ultimately establish non-viral delivery as a scalable platform for cell and gene therapies.
Zitieren
APA
Li, B. (2026). AI-driven LNP design: unlocking non-viral delivery for cell and gene therapy. Cell and Gene Therapy Insights, 12(6), 685-690. https://doi.org/10.18609/cgti.2026.082
Vancouver
Li B. AI-driven LNP design: unlocking non-viral delivery for cell and gene therapy. Cell and Gene Therapy Insights. 2026;12(6):685-690. doi:10.18609/cgti.2026.082
BibTeX
@article{Li2026,
author = {Li, Bowen},
title = {AI-driven LNP design: unlocking non-viral delivery for cell and gene therapy},
journal = {Cell and Gene Therapy Insights},
year = {2026},
volume = {12},
number = {6},
pages = {685--690},
doi = {10.18609/cgti.2026.082}
}
EUVIMED